CRNX - Crinetics hormone CRN04894 therapy shows promise in early-stage study

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported results from a multiple-ascending dose (MAD) portion of a phase 1 trial in healthy people of its oral adrenocorticotropic hormone (ACTH) CRN04894, being explored to treat Cushing’s disease, congenital adrenal hyperplasia (CAH). When the pituitary gland produces excess ACTH, it stimulates the adrenal glands to make more cortisol. Excess levels of the hormone cortisol in the body causes Cushing syndrome. The company said that after CRN04894 was given, data showed serum cortisol below normal levels and a marked reduction in 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations. The company evaluated 49 healthy adults in the MAD portion of the trial who were given 40, 60 or 80 mg doses of CRN04894, or placebo, daily for 10 days. People receiving the therapy experienced a dose-dependent suppression of adrenal function as measured by suppression of serum cortisol production of 17%, 29% and

For further details see:

Crinetics hormone CRN04894 therapy shows promise in early-stage study